Results 131 to 140 of about 12,992 (201)

Favorable Outcome With Eculizumab in Hemolytic Uremic Syndrome Presenting With Severe Neurological Complications: A Case Report. [PDF]

Case Rep Nephrol
Zaitoun M, Alanazi A, Kattash T, Wali A, Abdelbagi A, Batati SA, Faqeehi H, Zabali SA.   +7 more
europepmc   +1 more source

Efficacy and safety of crovalimab versus eculizumab in complement inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria: Chinese subgroup analysis of the phase 3 COMMODORE 2 study. [PDF]

Ann Hematol
Tong H, Lin Z, Yang C, Wang X, Sun J, Xia L, Shi J, Shi D, Zhang Z, Appius A, He G.   +10 more
europepmc   +1 more source

Clinical outcomes and quality of life associated with eculizumab in patients with late-onset myasthenia gravis. [PDF]

Front Immunol
Wang L, Qu M, Rong X, Sun X, Zhao Y, Huang S, Liu M.   +6 more
europepmc   +1 more source

Causes and outcomes of pediatric thrombotic microangiopathy. [PDF]

Res Pract Thromb Haemost
Scully M.
europepmc   +1 more source

Therapeutic advances in eculizumab for atypical hemolytic uremic syndrome: a narrative review. [PDF]

Front Pharmacol
Zhang D, Xiao Y, Ma H.
europepmc   +1 more source

Real-world efficacy of eculizumab in generalized myasthenia gravis patients with poor early response to efgartigimod: a prospective cohort study. [PDF]

Front Immunol
An X, Zhu L, Huang X, Zhang Z, Zhang Y, Zhang C.   +5 more
europepmc   +1 more source

Eculizumab in Myasthenia Gravis: A Multicenter Retrospective Real-World Study in China. [PDF]

Neurol Ther
Li Y, Yang H, Tan S, Luo L, Cao X, Hu J, Bu B, Chang T, Li Z.   +8 more
europepmc   +1 more source

Thrombotic Events in Patients With Paroxysmal Nocturnal Haemoglobinuria Using Eculizumab: A Post-Marketing Surveillance Sub-Analysis. [PDF]

EJHaem
Ikezoe T, Kawaguchi T, Hayashi H, Shimono A, Nishimura JI.   +4 more
europepmc   +1 more source

Successful rescue therapy with eculizumab for probable tislelizumab-related MMM overlap syndrome with dual positivity for anti-acetylcholine receptor and anti-titin antibodies: a case report and literature review. [PDF]

Front Immunol
Li YX, Hao YL.
europepmc   +1 more source

A decade of complement inhibition in post-transplant atypical HUS: outcomes with eculizumab and ravulizumab. [PDF]

Clin Kidney J
Gopireddy NSR, Kumar A, Smith RJH, Nester CM, Thomas CP.   +4 more
europepmc   +1 more source